Circular RNA Vaccines against SARS-CoV-2 and Emerging Variants
This article has been Reviewed by the following groups
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
- Evaluated articles (ScreenIT)
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants of concern (VOC), such as Delta (B.1.617.2) and Omicron (B.1.1.529), has continued to drive the worldwide pandemic. Therefore, there is a high demand for vaccines with enhanced efficacy, high thermostability, superior design flexibility, and fast manufacturing speed. Here, we report a circular RNA (circRNA) vaccine that encodes the trimeric RBD of SARS-CoV-2 Spike protein. Without the need of nucleotide modification, 5’-capping or 3’-polyadenylation, circRNA could be rapidly produced via in vitro transcription and is highly thermostable whether stored in naked or lipid-nanoparticle (LNP)-encapsulated format. LNP-encapsulated circRNA RBD elicited potent neutralizing antibodies and T cell responses, providing robust protection against Beta (B.1.351) and native viruses in mice and rhesus macaques, respectively. Notably, circRNA vaccine enabled higher and more durable antigen production than 1mΨ-modified mRNA vaccine, eliciting a higher proportion of neutralizing antibodies and stronger Th1-biased immune responses. Importantly, we found that circRNA RBD-Omicron vaccine induced effective neutralizing antibodies against only Omicron but not Delta variant. By contrast, circRNA RBD-Delta could elicit high level of neutralizing antibodies against both Delta and Omicron. Following two doses of either native- or Delta-specific vaccination, circRNA RBD-Delta , but not Omicron or Beta vaccines, could effectively boost the neutralizing antibodies against both Delta and Omicron variants. These results suggest that circRNA RBD-Delta is a favorable choice for vaccination to provide a broad-spectrum protection against the current variants of concern of SARS-CoV-2.
Article activity feed
-
SciScore for 10.1101/2021.03.16.435594: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IACUC: The animal experiments were approved by Peking University Laboratory Animal Center (Beijing), and undertaken in accordance with the National Institute of Health Guide for Care and Use of Laboratory Animals. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable For mouse vaccination, groups of 6-8 week-old female BLAB/c mice were intramuscularly immunized with LNP-circRNARBD (10 μg, N = 5; 50 μg, N = 5), or Placebo (empty LNP, N = 5) in 150 μL using a 1 mL sterile syringe, and 2 weeks later a second dose was immunized to boost the immune responses. Cell Line Authentication not detected. Table 2: Resources
… SciScore for 10.1101/2021.03.16.435594: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IACUC: The animal experiments were approved by Peking University Laboratory Animal Center (Beijing), and undertaken in accordance with the National Institute of Health Guide for Care and Use of Laboratory Animals. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable For mouse vaccination, groups of 6-8 week-old female BLAB/c mice were intramuscularly immunized with LNP-circRNARBD (10 μg, N = 5; 50 μg, N = 5), or Placebo (empty LNP, N = 5) in 150 μL using a 1 mL sterile syringe, and 2 weeks later a second dose was immunized to boost the immune responses. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources The SARS-CoV-2-specific IgG antibody titer was measured by ELISA. SARS-CoV-2-specific IgGsuggested: NoneCells were then washed in stain buffer (PBS supplemented with 2.5% FBS) and suspended in Fc Block for 5 min at RT prior to staining with a surface stain of following antibodies: CD3 (Invitrogen, 45-0031-82)/CD4 (BD, 562285)/CD8 (BD, 553035)/CD69 (BD, 557392)/CD44 (BD, 563058)/CD62L (BD, 560507). CD3suggested: (Abcam Cat# ab52305, RRID:AB_955118)Experimental Models: Cell Lines Sentences Resources circRNA transfection in vitro: For the circRNA transfection in HEK293T or NIH3T3 cells, 3×105 cells per well were seeded in 12-well plates. NIH3T3suggested: NoneThen the supernatant of HEK293T-hACE2 cells were removed and the mixer of serum and pseudovirus were added to each well. 36-48 hr later, the luciferase activity, which reflecting the degree of SARS-CoV-2 pseudovirus transfection, was measured using the Nano-Glo Luciferase Assay System (Promega). HEK293T-hACE2suggested: NoneBriefly, serum was diluted at 1:100 with 5 additional serial 5-fold dilution, and incubated with the same volume of pseudovirus with a TCID50 of 1.3×104 for 60 min at 37°C. 20,000 Huh-7 cells/well were cultured with mixture at 37°C for 24 h. Huh-7suggested: NoneExpression of neutralizing nanobodies or ACE2 decoys by circular RNAs: HEK293T cells were transfected with circular RNA in transfection reagent. HEK293Tsuggested: NCBI_Iran Cat# C498, RRID:CVCL_0063)Experimental Models: Organisms/Strains Sentences Resources Mouse vaccination and serum collection: The BALB/c mice were ordered from Beijing Vital River Laboratory Animal Technology Co., Ltd. BALB/csuggested: RRID:IMSR_ORNL:BALB/cRl)For mouse vaccination, groups of 6-8 week-old female BLAB/c mice were intramuscularly immunized with LNP-circRNARBD (10 μg, N = 5; 50 μg, N = 5), or Placebo (empty LNP, N = 5) in 150 μL using a 1 mL sterile syringe, and 2 weeks later a second dose was immunized to boost the immune responses. BLAB/csuggested: NoneSoftware and Algorithms Sentences Resources The half-neutralization titer of serum (NT50) was determined using four-parameter nonlinear regression in Prism 8 (GraphPad). GraphPadsuggested: (GraphPad Prism, RRID:SCR_002798)Relative luciferase units (RLU) were normalized to untreated groups, and analyzed by four-parameter nonlinear regression in Prism (GraphPad). Prismsuggested: (PRISM, RRID:SCR_005375)For the neutralization assay of circRNAnAB or circRNAACE2 decoys, the HEK293T-hACE2 cells were seeded in 96-well plates (50,000 cells/well) and incubated for approximate 24 hr until reaching over 90% confluent. circRNAnABsuggested: NoneAnalysis was performed using FlowJo software. FlowJosuggested: (FlowJo, RRID:SCR_008520)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).
Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on page 19. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
